Bluebird’s $2.8M Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia
XTalks
AUGUST 19, 2022
But bluebird bio has said such setbacks are expected for a company at the frontier of developing gene therapies for rare diseases. Live and On-Demand: Tuesday, October 4, 2022, at 11am EDT (4pm BST/UK). Zynteglo’s hefty price tag of $2.8 XTALKS WEBINAR: How Agile Clinical Trials Unlock Universal Access to Rare Disease Research.
95 
Let's personalize your content